10 results about "Cellular transplantation" patented technology

A cell transplanting kit includes a transplant including a cell group and a cell transplanting device. The cell transplanting device includes a needle-shaped portion that extends in a shape of a tube, and an aspiration portion configured to aspirate an interior of the needle-shaped portion. The needle-shaped portion is configured to attract the transplant by aspiration by the aspiration portion and take the transplant into the interior. The aspiration portion is configured to create an aspiration pressure in a range of −100 kPa to −0.1 kPa. The transplant includes a protection portion in a form of a gel covering at least a part of the cell group. The transplant has an outer diameter that is greater than or equal to a minimum value of the inner diameter of the needle-shaped portion. The protection portion has a jelly strength of greater than or equal to 100 g.

The present disclosure relates to methods of treating, preventing, or modulating diabetes in a patient in need thereof using a device for transplanting cells into a host body, specifically a method of treating diabetes in a patient in need thereof, comprising: implanting a device in the patient, wherein the device comprises: a porous scaffold comprising an immunologically compatible polymer mesh forming the walls of at least one chamber, an opening at either or both of a proximal end and a distal end of the chamber, at least one removable, non-porous plug configured to be positioned within the lumen of the at least one chamber, maintaining the device in the patient's body until the device is infiltrated with vascular and connective tissues; and infusing the chamber with cells, wherein at least some of the cells express insulin

The present invention aims to provide a cell inoculum and a cell transplantation substrate which can be subcultured without causing cell transformation and can effectively implant cells. An inoculum and a transplantation substrate containing a phenolphthalein derivative for facilitating implantation of cultured corneal endothelial cells or corneal endothelial replacement cells. The inoculum and the transplantation substrate can facilitate adhesion of cells during subculture and implantation of cells during transplantation.

This invention specifically provides antibodies or antigen-binding fragments thereof that are specific to CD45. The antibodies include monospecific antibodies to CD45 and antibodies with dual complementary sites to CD45. The antibodies are typically capable of binding to both human and cynomolgus monkey CD45. The antibodies of this invention have various uses, including targeting, exhausting, and killing cells expressing CD45, particularly for the treatment of cancers or autoimmune diseases mediated by CD45-positive cells, or prior to cell transplantation.

The present invention relates to cross-linked polymers (e.g., hydrogels) including hyaluronan polymer and multimeric cross-linker for treating disorders (e.g., retinal detachment or osteoarthritis), for use in screening models (e.g., in vitro cell culture system), or for cell transplantation (e.g., in vivo cell delivery).

A three-dimensional cell growth containment article is described, which includes a molded body channelized by removal of sacrificial channelizing element(s) therefrom, so that the molded body contains one or more channel(s) therein, with a matrix material in at least one of such channel(s) that is supportive of three-dimensional cell growth in the matrix material. A method for making such articles is also described, in which a molded body is formed with one or more sacrificial channelizing element(s) therein, following which the sacrificial channelizing element(s) are removed. The three-dimensional cell growth containment articles of the present disclosure may be utilized in any applications in which there exists a need to reproducibly generate three-dimensional cellular structures, e.g., islet transplantation for diabetes treatment, transplantation of hormone secreting cells, cellular scaffolds for wound healing, and generation of tissue engineering structures to regain structural usefulness for orthopedic applications.

Compositions and methods of transplanting cells by grafting strategies into solid organs (especially internal organs) are provided. These methods and compositions can be used to repair diseased organs or to establish models of disease states in experimental hosts. The method involves attachment onto the surface of a tissue or organ, a patch graft, a “bandaid-like” covering, containing epithelial cells with supporting early lineage stage mesenchymal cells. The cells are incorporated into soft gel-forming biomaterials prepared under serum-free, defined conditions comprised of nutrients, lipids, vitamins, and regulatory signals that collectively support stemness of the donor cells. The graft is covered with a biodegradable, biocompatible, bioresorbable backing used to affix the graft to the target site. The cells in the graft migrate into and throughout the tissue such that within a couple of weeks they are uniformly dispersed within the recipient (host) tissue. The mechanisms by which engraftment and integration of donor cells into the organ or tissue involve multiple membrane-associated and secreted forms of MMPs.

The invention relates to a long-acting hydrogen release system for assisting cell transplantation as well as a preparation method and application thereof, belongs to the technical field of medical treatment, and provides a long-acting hydrogen release system for assisting cell transplantation in order to provide a substance capable of performing targeted delivery to a cell transplantation part and continuously releasing high-dose H2. The long-acting hydrogen release system comprises a hydrogen release material with a particle size of 5 nm to 10 [mu] m and a hydrogel matrix, and the cells are dispersed in the system; the concentration of the hydrogen release material is 0.01 to 100 [mu] g / mL, and the content of the cells is 10000 to 100000000 cells / mL. The long-acting hydrogen release system is used for maintaining the activity and directional differentiation of transplanted cells in an in-vitro differentiation / balling process and maintaining the activity and characteristics of the transplanted cells in a pathological microenvironment after transplantation. In a malignant pathological microenvironment, hydrogen is continuously supplied, so that the activity of stem cell spheres assembled / differentiated into cartilage cell microspheres and the hyaline cartilage phenotype are effectively maintained, and the activity of transplanted stem cells and the hyaline cartilage differentiation potential are maintained by continuously supplying hydrogen; and continuously supplying hydrogen to maintain the activity and transparency of the transplanted cartilage cells.

A system and methods are provided for amniotic grafts for encouraging healing of incisions applied to the feet, ankles, and other parts of the body. The amniotic graft comprises a multi-layer matrix and a shape for treating the incisions. The amniotic graft comprises an acellular amniotic membrane or a cellular amniotic membrane. The multi-layer matrix comprises an amnion or chorion layer that enables rapid remodeling of soft-tissue wounds. A spongy layer separates a fibroblast layer and the amnion or chorion layer. The multi-layer matrix includes a compact layer, a basement membrane, and an epithelium. The shape comprises a rectangle having a width and length that are suitable for treating the incision. The amniotic grafts can be sterile packaged with sterile instruments for implanting the grafts to treat soft-tissue wounds. The wound can include surgical incisions, muscle strains, as well as tendon and ligament disruption to various locations of the body.

Cranial placodes are embryonic structures essential for sensory and endocrine organ development. The efficient derivation of cranial placodes from human pluripotent stem cells is disclosed where the timed removal of the BMP inhibitor Noggin, a component of the dual-SMAD inhibition strategy of neural induction, triggers placode induction at the expense of CNS fates. Further fate specification at the pre-placode stage enables the selective generation of placode-derived trigeminal ganglia capable of in vivo engraftment, mature lens fibers and anterior pituitary hormone-producing cells that upon transplantation produce hormones including, but not limited to, human growth hormone and adrenocortiocotropic hormone in vivo. Alternatively, anterior pituitary hormone-producing cells are generated in cell culture systems in vitro.